Compare Vanguard Emerging Markets Stock Index Fund ETF (VWO) vs State Street SPDR S&P Biotech ETF (XBI) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Vanguard Emerging Markets Stock Index Fund ETF vs State Street SPDR S&P Biotech ETF — how do they compare? Vanguard Emerging Markets Stock Index Fund ETF trades at $59.74 (market cap $168.50B), while State Street SPDR S&P Biotech ETF trades at $153.7 (market cap $10.11B). The key difference: Vanguard Emerging Markets Stock Index Fund ETF is far larger — about 16.7× State Street SPDR S&P Biotech ETF's market cap, and State Street SPDR S&P Biotech ETF is more actively traded (12,903,266 versus 9,650,999). Which is the better fit depends on your goals — on Pluang, investors hold Vanguard Emerging Markets Stock Index Fund ETF for 135 Days and State Street SPDR S&P Biotech ETF for 38 Days on average.
| VWO | XBI | |
|---|---|---|
Market Cap | $168.50B | $10.11B |
Volume | 9,650,999 | 12,903,266 |
52-Week High | $61.44 | $169.55 |
52-Week Low | $52.42 | $104.99 |
Typical Hold Time | 135 Days | 38 Days |
Sector | — | Broad Market / Factor |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
VWO trades at $59.76, down 0.15% on the day, with technical indicators showing a bearish bias as moving averages signal selling pressure. The ETF's emerging markets focus faces headwinds from China's economic slowdown, though AI-driven semiconductor demand in Taiwan provides some offset. Recent institutional buying by firms like Allianz and Alamar Capital suggests confidence in long-term emerging markets exposure despite near-term challenges.
The outlook remains cautious given China's persistent weakness and technical bearish signals, though institutional accumulation and AI infrastructure spending offer potential catalysts. Key risks include concentrated emerging markets exposure and currency volatility, requiring careful position sizing for investors seeking diversification beyond developed markets.
XBI trades at $153.75, up 2.34% today, but technical indicators signal a bearish trend with resistance at $154. The ETF's modified equal-weight structure provides exposure to over 150 biotech companies, benefiting from M&A activity and positive clinical catalysts like the Merck-Moderna cancer vaccine breakthrough.
Outlook remains mixed with 100% analyst hold rating contrasting with bullish news catalysts. Key risks include high volatility, sector-specific regulatory pressures, and expense ratios higher than broader healthcare ETFs. The current technical setup near resistance requires monitoring for breakout confirmation.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
About Vanguard Emerging Markets Stock Index Fund ETF
The fund employs an indexing investment approach designed to track the performance of the FTSE Emerging Markets All Cap China A Inclusion Index. It invests by sampling the index, meaning that it holds a broadly diversified collection of securities that, in the aggregate, approximates the index in terms of key characteristics.
Read more on VWO →About State Street SPDR S&P Biotech ETF
XBI is an equal-weighted ETF that tracks the U.S. biotechnology segment. It provides diversified exposure to small, mid, and large-cap biotech firms involved in drug discovery and medical research, such as Moderna and Exact Sciences.
Read more on XBI →
